TICKERNERD
Menu
VSTMVSTMHealthcare · Biotechnology

VSTM Stock Forecast: Verastem, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$6.58
−1.35% on the day

The 9 Wall Street analysts covering Verastem, Inc. hold a median 12-month price target of $15 — +128.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 56 of 100 as at 15 Aug 2026 — in the upper half.

Market cap
$595.9M
Ticker Nerd rank
56 / 100
Median analyst target
$15
Analysts covering
9
Total return, dividends reinvested
1W
−2.4%
1M
+18.1%
YTD
−14.8%
1Y
−14.9%
From 52W high
−38.9%
From 52W low
+90.7%
$3
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VSTM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Verastem, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
56 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
89
Value
67
Accruals
56
Revisions
52
Size
52
Momentum
48
Volatility
47
Quality
38
Issuance
34

Growth (89): Sales and profits are climbing, and climbing faster than before.

Issuance (34): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VSTM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VSTM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Oct 25Jan 26Apr 26Jul 26VSTMHigh $18Median $15Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $9Median $15High $18

The green dot is the last close — the median target sits +128.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
11 Aug 2026MizuhoMaintainsOutperform$14 → $13
7 Aug 2026GuggenheimMaintainsBuy$14 → $12
7 July 2026RBC CapitalMaintainsOutperform$15 → $14
7 July 2026RBC CapitalMaintainsOutperform—
2 July 2026BTIGMaintainsBuy—
2 July 2026BTIGMaintainsBuy$18
24 June 2026BTIGReiteratesBuy—
24 June 2026HC Wainwright & Co.ReiteratesBuy—
23 June 2026JefferiesMaintainsBuy—
14 May 2026MizuhoMaintainsOutperform—
8 May 2026BTIGMaintainsBuy—
23 Apr 2026BTIGReiteratesBuy—
20 Apr 2026BTIGReiteratesBuy—
10 Apr 2026BTIGReiteratesBuy—
10 Apr 2026HC Wainwright & Co.ReiteratesBuy—
30 Mar 2026JefferiesAssumesBuy$19 → $15
12 Mar 2026BTIGAssumesBuy$19
4 Feb 2026HC Wainwright & Co.AssumesBuy$18
16 Oct 2025Cantor FitzgeraldAssumesOverweight—
9 Sept 2025BTIGReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VSTM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

VSTM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Verastem, Inc. (VSTM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.2×

Cheaper than 85% of US stocks

Price / sales
6.8×

Cheaper than 20% of US stocks

Price / book
11.9×

Cheaper than 9% of US stocks

EV / EBITDA
−3.5×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
1775.4%

Higher than 99% of US stocks

Earnings growth (YoY)
1775.4%

Higher than 98% of US stocks

Gross margin
89.9%

Higher than 96% of US stocks

Operating margin
−81.6%

Higher than 14% of US stocks

Net margin
−231.6%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−471.2%

Higher than 3% of US stocks

Return on assets
−49.6%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

VSTM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VSTMVerastem, Inc.$595.9M
56
ARVNArvinas, Inc.$576.1M
84
ALTAltimmune, Inc.$571.4M
23
CRMDCorMedix, Inc.$590.7M
59
PRMEPrime Medicine, Inc.$560.5M
35
NVCTNuvectis Pharma, Inc.$597.7M
68
EIKNEikon Therapeutics, Inc.$597.8M
2

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Verastem, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VSTM news & analysis

Verastem Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

Verastem reported second-quarter 2026 net product revenue of $25.1 million from sales of its AVMAPKI FAKZYNJA CO-PACK. The company attributed the result to increased new patient starts, refills, and physician adoption, describing it as a rebound in commercial performance.

Why it matters — A VSTM watcher would care because the quarterly revenue figure and improved patient/physician trends signal the commercial momentum of its co-pack product.

Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Verastem, Inc. (VSTM) held its Q2 2026 earnings call, and the transcript of that call was published via Seeking Alpha. The transcript covers the company's second-quarter 2026 financial results and management commentary.

Why it matters — The Q2 2026 earnings call transcript provides Verastem watchers with the company's latest financial results and management's official statements.

Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 6 Aug 2026positive

Verastem reported a second-quarter loss of $0.35 per share, narrower than the Zacks Consensus Estimate of a $0.46 loss, and compares with a $0.39 loss a year ago. The company beat revenue estimates for the quarter.

Why it matters — The narrower-than-expected loss indicates the company's quarterly performance came in ahead of analyst forecasts, which is relevant for investors tracking its financial trajectory.

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Business Wire · 6 Aug 2026positive

Verastem Oncology reported its financial results for the second quarter ended June 30, 2026, and highlighted recent business progress across its commercial business and pipeline programs. The company cited strong quarter-over-quarter growth for AVMAPKI FAKZYNJA CO-PACK driven by new patient starts.

Why it matters — VSTM watchers would care because the company indicated meaningful commercial progress and quarter-over-quarter growth for its approved product, which reflects ongoing execution of its business strategy.

Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer

Business Wire · 28 July 2026positive

Verastem Oncology announced it has dosed the first patient in the TARGET-D 203 Phase 2 registration-directed trial of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, for KRAS G12D-mutated metastatic colorectal cancer.

Why it matters — This milestone moves Verastem's VS-7375 candidate into a registration-directed trial, which could support a future regulatory submission if successful.

FAQ

Frequently asked questions about VSTM stock

What is the VSTM stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Verastem, Inc. have a median 12-month price target of $15, with estimates ranging from $9 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VSTM stock a buy right now?

Of the 9 analysts covering Verastem, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Verastem, Inc. 56 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VSTM?

As at 15 Aug 2026, Verastem, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (89 of 100).

Will VSTM stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +128.0% from the last close, and Ticker Nerd's factor model ranks Verastem, Inc. 56 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VSTM stock forecast for 2030?

No analyst covering Verastem, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VSTM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $18 over the next 12 months.

How has VSTM stock performed over the past year?

Verastem, Inc. returned -14.9% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Verastem, Inc. do?

Verastem Inc. is a biopharmaceutical company that concentrates on developing and commercializing innovative cancer therapies.

What is the latest news on VSTM?

The most recent item we track (MarketBeat, 7 Aug 2026): "Verastem Q2 Earnings Call Highlights". Verastem reported second-quarter 2026 net product revenue of $25.1 million from sales of its AVMAPKI FAKZYNJA CO-PACK. The company attributed the result to increased new patient starts, refills, and physician adoption, describing it as a rebound in commercial performance.

Company

About Verastem, Inc.

Verastem Inc. is a biopharmaceutical company that concentrates on developing and commercializing innovative cancer therapies. Its primary focus is on creating treatments targeting cancer cell survival and division pathways, specifically in hematologic malignancies and solid tumors. Key products in its pipeline include small molecule inhibitors that aim to disrupt cancer cell signaling and replication processes. Verastem Inc. plays a pivotal role within the healthcare and biotechnology sectors, contributing to advancements in precision medicine through its targeted therapies. Headquartered in Needham, Massachusetts, Verastem's research and development efforts are geared towards addressing unmet needs in oncology by providing new options for patients, thereby enhancing its importance in the biopharmaceutical market landscape. As it continues to make strides in cancer treatment, Verastem Inc. remains an integral player in the ongoing quest for more effective cancer solutions.

CEO Mr. Daniel W. Paterson · 102 employees · United States · https://www.verastem.com